Chemical Compound Review:
Bamalite 2-[[3-methyl-4-(2,2,2- trifluoroethoxy)pyri...
Synonyms:
Lansopep, Lasoprol, Limpidex, Mesactol, PrevOnco, ...
Ohkusa,
Takashimizu,
Fujiki,
Suzuki,
Shimoi,
Horiuchi,
Sakurazawa,
Ariake,
Ishii,
Kumagai,
Tanizawa,
Arkkila,
Seppälä,
Kosunen,
Sipponen,
Mäkinen,
Rautelin,
Färkkilä,
Agrawal,
Campbell,
Safdi,
Lukasik,
Huang,
Haber,
Sohn,
Kwon,
Kim,
Ishizaki,
Graham,
Agrawal,
Campbell,
Haber,
Collis,
Lukasik,
Huang,
Endo,
Yoshida,
Ohmi,
Higuchi,
- Activity of lansoprazole against Helicobacter pylori. Megraud, F., Boyanova, L., Lamouliatte, H. Lancet (1991)
- Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Eissele, R., Brunner, G., Simon, B., Solcia, E., Arnold, R. Gastroenterology (1997)
- Lansoprazole, H. pylori, and atrophic gastritis. Kuipers, E.J., Klinkenberg-Knol, E.C., Festen, H.P., Meuwissen, S.G. Gastroenterology (1997)
- Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Robinson, M., Lanza, F., Avner, D., Haber, M. Ann. Intern. Med. (1996)
- The prophylactic use of a proton pump inhibitor before food and alcohol. O'Leary, C., McCarthy, J., Humphries, M., Shanahan, F., Quigley, E. Aliment. Pharmacol. Ther. (2003)
- Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers. Arkkila, P.E., Seppälä, K., Kosunen, T.U., Sipponen, P., Mäkinen, J., Rautelin, H., Färkkilä, M. European journal of gastroenterology & hepatology. (2005)
- A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy. Yang, J.C., Yang, K.C., Hsu, C.T., Wang, C.S., Kuo, C.F., Wang, T.H. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. (1999)
- Acid secretion from an esophageal inlet patch demonstrated by ambulatory pH monitoring. Galan, A.R., Katzka, D.A., Castell, D.O. Gastroenterology (1998)
- Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial. Ohkusa, T., Takashimizu, I., Fujiki, K., Suzuki, S., Shimoi, K., Horiuchi, T., Sakurazawa, T., Ariake, K., Ishii, K., Kumagai, J., Tanizawa, T. Ann. Intern. Med. (1998)
- Effect of anti-ulcer drugs on DNA synthesis in adult normal human hepatocytes in culture. Blanc, P., Liautard, J., Greuet, J., Daures, J.P., Fabre, J.M., Larrey, D., Michel, H., Maurel, P. Hepatology (1995)
- Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole. Nelson, W.W., Vermeulen, L.C., Geurkink, E.A., Ehlert, D.A., Reichelderfer, M. Arch. Intern. Med. (2000)
- Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Agrawal, N.M., Campbell, D.R., Safdi, M.A., Lukasik, N.L., Huang, B., Haber, M.M. Arch. Intern. Med. (2000)
- Effects of sucralfate, lansoprazole, and cimetidine on the delayed healing by hydrocortisone sodium phosphate of chronic gastric ulcers in the rat. Kuwayama, H., Matsuo, Y., Eastwood, G.L. Am. J. Med. (1991)
- Hypersensitivity to lansoprazole and rabeprazole with tolerance to other proton pump inhibitors. Pérez Pimiento, A.J., Prieto Lastra, L., Rodríguez Cabreros, M.I., González Sánchez, L.A., Mosquera, M.R., Cubero, A.G. J. Allergy Clin. Immunol. (2006)
- Effects of lansoprazole and amoxicillin on uptake of [(14)C]clarithromycin into gastric tissue in rats. Endo, H., Yoshida, H., Ohmi, N., Higuchi, S. Antimicrob. Agents Chemother. (2001)
- Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Tran, A., Rey, E., Pons, G., Pariente-Khayat, A., D'Athis, P., Sallerin, V., Dupont, C. Clin. Pharmacol. Ther. (2002)
- Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Furuta, T., Shirai, N., Watanabe, F., Honda, S., Takeuchi, K., Iida, T., Sato, Y., Kajimura, M., Futami, H., Takayanagi, S., Yamada, M., Ohashi, K., Ishizaki, T., Hanai, H. Clin. Pharmacol. Ther. (2002)
- Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. Ko, J.W., Jang, I.J., Shin, J.G., Nam, S.K., Shin, S.G., Flockhart, D.A. Clin. Pharmacol. Ther. (1999)
- Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. Kim, K.A., Shon, J.H., Park, J.Y., Yoon, Y.R., Kim, M.J., Yun, D.H., Kim, M.K., Cha, I.J., Hyun, M.H., Shin, J.G. Clin. Pharmacol. Ther. (2002)
- Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status. Sohn, D.R., Kwon, J.T., Kim, H.K., Ishizaki, T. Clin. Pharmacol. Ther. (1997)
- Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Berstad, A.E., Hatlebakk, J.G., Maartmann-Moe, H., Berstad, A., Brandtzaeg, P. Gut (1997)
- Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologic responses. Bergmann, J.F., Chassany, O., Simoneau, G., Lemaire, M., Segrestaa, J.M., Caulin, C. Clin. Pharmacol. Ther. (1992)
- Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Langtry, H.D., Wilde, M.I. Drugs (1997)
- An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Brunner, G., Arnold, R., Hennig, U., Fuchs, W. Aliment. Pharmacol. Ther. (1993)
- Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Richter, J.E., Campbell, D.R., Kahrilas, P.J., Huang, B., Fludas, C. Arch. Intern. Med. (2000)
- Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Graham, D.Y., Agrawal, N.M., Campbell, D.R., Haber, M.M., Collis, C., Lukasik, N.L., Huang, B. Arch. Intern. Med. (2002)
- Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points. Hawkey, G.M., Cole, A.T., McIntyre, A.S., Long, R.G., Hawkey, C.J. Gut (2001)
- Lansoprazole pharmacokinetics in subjects with various degrees of kidney function. Karol, M.D., Machinist, J.M., Cavanaugh, J.M. Clin. Pharmacol. Ther. (1997)
- Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Desta, Z., Zhao, X., Shin, J.G., Flockhart, D.A. Clinical pharmacokinetics. (2002)
- Identification of the human P450 enzymes involved in lansoprazole metabolism. Pearce, R.E., Rodrigues, A.D., Goldstein, J.A., Parkinson, A. J. Pharmacol. Exp. Ther. (1996)
- Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. Curi-Pedrosa, R., Daujat, M., Pichard, L., Ourlin, J.C., Clair, P., Gervot, L., Lesca, P., Domergue, J., Joyeux, H., Fourtanier, G. J. Pharmacol. Exp. Ther. (1994)
- Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Laine, L., Estrada, R., Trujillo, M., Knigge, K., Fennerty, M.B. Ann. Intern. Med. (1998)
- Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Wong, W.M., Wong, B.C., Hung, W.K., Yee, Y.K., Yip, A.W., Szeto, M.L., Fung, F.M., Tong, T.S., Lai, K.C., Hu, W.H., Yuen, M.F., Lam, S.K. Gut (2002)
- Influence of lansoprazole treatment on diazepam plasma concentrations. Lefebvre, R.A., Flouvat, B., Karolac-Tamisier, S., Moerman, E., Van Ganse, E. Clin. Pharmacol. Ther. (1992)